آنکوژن یار
OncoGeneAid

"آنکوژن" امکان درمان هدفمند
را برای بیماران فراهم می‌کند.

GENETIC TESTING REPORT FOR

General Information

Patient:	[redacted]	**Gender:**	Female
Age:	39	**Clinic/Hospital:**	[redacted]
Diagnosis:	Ovarian Cancer		
Sample Site:	Ovarian	**Sample Type:**	FFPE

TEST CONTENT:

OncoGene CDx BRCA analyzes BRCA1/2 genes by next-generation sequencing, providing the latest therapeutic knowledge.

KEY RESULTS

Genomic Findings*

0 somatic mutations

0 germline mutation related with ovarian cancer

Targeted Drugs

Favorable: None

Resistant: None

Controversial: None

* For a complete list of the genes assayed, please refer to Appendix

Unit 5, number 4, Gol dead-end, Golestan street, Tehran, Iran.

+98 21 6603 3184

GUIDANCE FOR TARGETED DRUGS

Genomic Findings Detected	FDA-Approved Therapies (for Patient's Cancer)		FDA-Approved Therapies (for Other Cancer)	Phase II/III Clinical Trials	Others
	Sensitive	Resistant	Sensitive	Sensitive	Sensitive
None	None	None	None	None	None

SOMATIC MUTATION

Gene	Nucleotide change	Amino Acid change	Gene Region	Frequency
None	None	None	None	None

GERMLINE MUTATION ASSOCIATED WITH HEREDITARY CANCER

Disease	Gene	Amino Acid change	Function Change	Gene Region	Hom/Het	Class
Ovarian Cancer	None	None	None	None	None	None

Unit 5, number 4, Gol dead-end, Golestan street, Tehran, Iran.
+98 21 6603 3184

INTERPRETATION

Targeted Drugs

FDA-APPROVED THERAPIES FOR PATIENT'S CANCER

DRUGS	THERAPEUTIC EFFECT PREDICTION	INTERPRETATION
None	None	None

FDA-APPROVED THERAPIES FOR OTHER CANCER

DRUGS	THERAPEUTIC EFFECT PREDICTION	INTERPRETATION
None	None	None

PHASE II/III CLINICAL TRIALS

DRUGS	THERAPEUTIC EFFECT PREDICTION	INTERPRETATION
None	None	None

OTHERS

DRUGS	THERAPEUTIC EFFECT PREDICTION	INTERPRETATION
None	None	None

Unit 5, number 4, Gol dead-end, Golestan street, Tehran, Iran.
+98 21 6603 3184

Genomic Alterations

SOMATIC MUTATION		
GENETIC ALTERATION	**INTERPRETATION**	**DESCRIPTION**
None	None	None

GERMLINE MUTATION ASSOCIATED WITH HEREDITARY CANCER		
GENE	**INTERPRETATION**	**DESCRIPTION**
BRCA1	None	None
BRCA2	None	None

Unit 5, number 4, Gol dead-end, Golestan street, Tehran, Iran.
+98 21 6603 3184

METHODS AND LIMITATIONS

OncoGene CDx BRCA is designed to analyze exons and selected intronic regions in BRCA1/2 genes. The assay will be updated periodically to reflect new knowledge about cancer biology.
The detected variations include single point mutation, small Indel, copy number variation and fusion gene.

Please Note:
This test is based on Next-Generation Sequencing technology. A specific mutation at mutant allele frequency over 1% can be detected. However, it may not provide detection of certain genes or portions of certain genes due to local sequence characteristics or the presence of closely related pseudo genes. The conclusions are based on the current scientific research all over the world and the references for clinical diagnosis, treatments, detection. The results are for reference only. Should there be any queries, please kindly contact your genetic consultant.

Unit 5, number 4, Gol dead-end, Golestan street, Tehran, Iran.
+98 21 6603 3184

APPENDIX

1. Common targeted therapy drugs recommended by NCCN Guidelines and related genetic mutations

1.1 Targeted drugs recommended by NCCN Guidelines for Ovarian Cancer (V2.2019)

Gene	Genetic mutation	Targeted therapy recommended by NCCN guidelines	Correlation
BRCA1	Mutant Type	Olaparib, Niaparib, Rucaparib	may be sensitive
BRCA2			

References

1. PMID: 24882434 Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
2. PMID: 30345884 Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
3. PMID: 30285518 First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
4. PMID: 25366685 Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
5. PMID: 27717299 Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
6. PMID: 30425037 BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
7. PMID: 28882436 Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
8. PMID: 28916367 Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
9. PMID: 30948273 Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Unit 5, number 4, Gol dead-end, Golestan street, Tehran, Iran.
+98 21 6603 3184